Roche’s Alnylam deal shows drug firms interested in heart drugs

AdobeRoche’sannouncementMondaythatitwouldpay$310millionforrightstoahypertensiontreatment,zilebesiran DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr




hotspot

author：fashion    Page View：15
Franklin faces
Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： UHS says company favors patients whose insurance pays more
Next article： In age of alternative facts, a scholarly course on calling out crap